Hualan Biological Engineering Inc. (SHE:002007)

Market Cap	26.57B -8.0%
Revenue (ttm)	4.60B +4.9%
Net Income	940.40M -13.6%
EPS	0.52 -13.4%
Shares Out	1.83B
PE Ratio	28.00
Forward PE	18.69
Dividend	1.00 (6.88%)
Ex-Dividend Date	Oct 27, 2025

Volume	9,512,470
Average Volume	10,039,740
Open	14.21
Previous Close	14.34
Day's Range	14.20 - 14.60
52-Week Range	14.14 - 18.39
Beta	0.47
RSI	37.29
Earnings Date	Mar 28, 2026

About SHE:002007

Hualan Biological Engineering Inc. researches, develops, produces, and commercializes blood products, vaccines, and genetic engineering products in China and internationally. The company offers human serum albumin to treat blood loss trauma, shock caused by burns, intracranial pressure and persistent, liver cirrhosis, and kidney disease; edema for hypoproteinemia, neonatal hyperbilirubinemia, cardiopulmonary bypass, adjuvant treatment of burns, hemodialysis, and human respiratory distress syndrome; intravenous human immunoglobulin (pH4) for imm...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 4,012
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002007

Financial Performance

In 2025, SHE:002007's revenue was 4.60 billion, an increase of 4.93% compared to the previous year's 4.38 billion. Earnings were 940.40 million, a decrease of -13.55%.